Journal: Antimicrobial Agents and Chemotherapy

Article Title: In Vivo Pharmacodynamic Target Assessment of Antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Neutropenic Murine Pneumonia Model

doi: 10.1128/AAC.01354-20

Figure Lengend Snippet: In vitro antimicrobial susceptibility results of S. aureus and S. pneumoniae strains selected for use in the murine lung infection studies a

Article Snippet: The elevated MICs to antofloxacin were mirrored by a similar increase in MICs to levofloxacin ( ). table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Organism Source Resistance MIC (mg/liter) of: ATX LEV CTX AZM S. aureus 29213 ATCC MSSA 0.125 0.25 2 1 43300 ATCC MRSA 0.125 0.25 64 512 MW2 ATCC, septicemia MRSA 0.063 0.25 128 1 SA 368 NPIN, sputum MRSA 0.25 2 32 16 S. pneumoniae 49619 ATCC PSSP 0.25 1 0.125 0.125 SP 18-1 NPIN, BAL PSSP 0.063 0.125 0.063 0.25 SP 18-2 NPIN, BAL PRSP 0.5 1 4 2 SP 18-3 NPIN, BAL PSSP 0.031 0.25 0.03 0.063 Open in a separate window a NPIN, National Pathogen Identification Network of China (courtesy of Guangdong Provincial Center for Disease Control and Prevention of China); BAL, bronchoalveolar lavage fluids; MSSA, methicillin-susceptible S. aureus ; MRSA, methicillin-resistant S. aureus ; PSSP, penicillin-susceptible S. pneumoniae ; PRSP, penicillin-resistant S. pneumoniae ; ATX, antofloxacin; LEV, levofloxacin; CTX, cefotaxime; and AZM, azithromycin.

Techniques: In Vitro, Infection